MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-10-2026
iBio General and Administrative Expenses 2011-2026 | IBIO
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses iBio
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.7 M | 11.7 M | 19 M | 21.8 M | 22 M | 12.4 M | 12.3 M | 10.7 M | 10.6 M | 7.68 M | 5.02 M | 4.2 M | 4.24 M | 5.62 M | 7.09 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 22 M | 4.2 M | 11 M |
Quarterly General and Administrative Expenses iBio
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.16 M | 2.5 M | - | 2.97 M | 2.74 M | 2.8 M | - | 2.72 M | 2.96 M | 3.55 M | - | 3.52 M | 7.79 M | 5.09 M | 12.9 M | 5.32 M | 5.37 M | 4.18 M | 9.55 M | 5.31 M | 5.66 M | 5.36 M | 5.81 M | 5.57 M | 2.58 M | 2.99 M | 2.58 M | 2.99 M | 3.39 M | 2.87 M | 3.39 M | 2.87 M | 2.59 M | 2.5 M | 2.59 M | 2.5 M | 2.35 M | 2.47 M | 2.35 M | 2.47 M | 1.68 M | 1.42 M | 1.68 M | 1.42 M | 1.3 M | 1.05 M | 1.3 M | 1.05 M | 1.05 M | 949 K | 1.05 M | 949 K | 1.04 M | 1.02 M | 1.04 M | 1.02 M | 1.75 M | 1.19 M | 1.75 M | 1.19 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 12.9 M | 949 K | 3.07 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
13.1 M | - | 1052.0 % | $ 415 M |  USA |
 |
Aeterna Zentaris
AEZS
|
5.92 M | - | 5.93 % | $ 314 M |  Canada |
 |
Albireo Pharma
ALBO
|
69.6 M | - | -0.23 % | $ 916 M | USA |
 |
I-Mab
IMAB
|
900 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
16.2 M | - | 2.54 % | $ 160 B |  France |
 |
Aileron Therapeutics
ALRN
|
13.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
Altimmune
ALT
|
28.1 M | $ 3.44 | 2.99 % | $ 303 M | USA |
 |
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
160 M | $ 218.06 | -1.72 % | $ 5 B |  Danmark |
 |
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | USA |
 |
Amgen
AMGN
|
7.05 B | $ 349.77 | 0.57 % | $ 188 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
85.9 M | $ 19.23 | -1.38 % | $ 899 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | USA |
 |
Amarin Corporation plc
AMRN
|
43.8 M | $ 14.6 | 0.76 % | $ 6.06 B |  Irlanda |
 |
AgeX Therapeutics
AGE
|
9.33 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
89.7 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
7.17 M | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - |  Russia |
 |
Inventiva S.A.
IVA
|
11.2 M | $ 6.08 | 5.19 % | $ 138 M | France |
 |
Adverum Biotechnologies
ADVM
|
63.1 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
12.7 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
12.2 M | - | -9.65 % | $ 45.9 M | USA |
 |
Avenue Therapeutics
ATXI
|
4.64 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
46.7 M | $ 1.4 | 2.19 % | $ 357 M | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
1.53 M | - | - | $ 7.46 M |  Israel |
 |
ChemoCentryx
CCXI
|
78.9 M | - | - | $ 3.74 B | USA |
 |
Aytu BioScience
AYTU
|
17.4 M | $ 2.63 | 0.77 % | $ 16.5 M | USA |
 |
Atreca
BCEL
|
31.5 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
100 M | - | - | $ 867 M | Germany |
 |
BeiGene, Ltd.
BGNE
|
2.08 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellerophon Therapeutics
BLPH
|
6.02 M | - | -74.18 % | $ 955 K | USA |
 |
Benitec Biopharma
BNTC
|
6.97 M | $ 11.19 | 1.91 % | $ 461 M | USA |
 |
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
15.9 M | $ 4.42 | 4.25 % | $ 734 M | Canada |
 |
Akouos
AKUS
|
22.2 M | - | 0.23 % | $ 488 M | USA |
 |
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Allakos
ALLK
|
45.1 M | - | - | $ 28.6 M | USA |
 |
Brickell Biotech
BBI
|
11.2 M | - | -5.38 % | $ 6.06 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
12.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Cabaletta Bio
CABA
|
29.6 M | $ 2.82 | -4.08 % | $ 3.29 M | USA |
 |
Calithera Biosciences
CALA
|
20.9 M | - | -10.95 % | $ 876 K | USA |
 |
Alpine Immune Sciences
ALPN
|
18 M | - | - | $ 2.17 B | USA |
 |
Cara Therapeutics
CARA
|
27.8 M | - | -3.03 % | $ 260 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
7.08 M | - | -11.43 % | $ 502 K | USA |
 |
AlloVir
ALVR
|
11 M | - | 4.14 % | $ 49.1 M | USA |